Dover Lifesciences

Company profile

Dover Lifesciences company profile

DLS is creating new drugs to treat metabolic and cardiovascular diseases by mimicking favorable genotypes/phenotypes in nature. Some people are thinner than others, and DLS has identified a mutation in humans that causes thinness. The mutation in the target protein causes loss-of-function leading to the wasting of energy in the body and results in thinness. DLS is in the process of creating a small molecule inhibitor to the target protein that will similarly cause an inefficient metabolism and lead to thinness regardless of the cause of obesity. Following nature's example provides a safer path to curing obesity.